Ptc Therapeutics (PTCT) EBIT Growth (1y) (2013 - 2026)
Powered by 
Analysis
Ptc Therapeutics (PTCT) EBIT Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -36.55% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 99.51% |
| 10 | Ptc Therapeutics | 5.79 Bn | 3.56 Bn | 340.60 Mn | 526.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 526.17% |
| Mar 31, 2026 | -95.37% |
| Dec 31, 2025 | 56.06% |
| Sep 30, 2025 | 105.53% |
| Jun 30, 2025 | 13.08% |
| Mar 31, 2025 | 2,234.57% |
| Dec 31, 2024 | -2,890.19% |
| Sep 30, 2024 | 53.87% |
| Jun 30, 2024 | 80.81% |
| Mar 31, 2024 | 61.35% |
| Dec 31, 2023 | 102.91% |
| Sep 30, 2023 | -73.29% |
| Jun 30, 2023 | -126.87% |
| Mar 31, 2023 | -35.94% |
| Dec 31, 2022 | -136.45% |
| Sep 30, 2022 | 26.74% |
| Jun 30, 2022 | 6.22% |
| Mar 31, 2022 | 11.85% |
| Dec 31, 2021 | 12.08% |
| Sep 30, 2021 | -68.83% |